Expectation of Ethical Conduct
Purpose and Scope
General Information
Manuscript Categories
Manuscript Submission Procedures
Manuscript Preparation
General Format
Title Page
Abstract
Introduction
Results and Discussion
Materials and Methods
Acknowledgments
References
Tables
Figures and Legends
Supplemental Data
Units of Measure
Standard Abbreviations
Editorial Policies and Guidelines
Prior Publication
Authorship Criteria
Guidelines for
considering authors of non-research articles who have a potential COI
Obligations of Reviewers
Experimental Subjects
Experimental Animals
Manuscripts Reporting New
Amino Acid or Nucleotide Sequence
Manuscripts Reporting
Novel Compounds
Genomic and Proteomic Papers
Validation of Data and
Statistical Analysis
Digital Image Integrity
Publication and Production Guidelines
Proofs and Reprints
Page and Color Charges
NIH Deposits
Wellcome Trust
Institutional Repositories and Other Archives
Journal Facts
The Endocrine Society's mission is to advance excellence in endocrinology and be an integrative force in scientific research and medical practice. Such progress depends on integrity in the conduct of scientific research and truthful representation of findings. Specific guidelines regarding the Society's expectations for ethical conduct can be found in the Code of Ethics of The Endocrine Society and the Ethical Guidelines for Publications of Research. The journal editors and publication oversight committees of The Endocrine Society are dedicated to upholding high ethical standards in its publications and expect authors and reviewers to do the same.
Molecular Endocrinology is devoted to the rapid publication of manuscripts that use molecular approaches to study the mechanism of action of hormones and related substances as well as the regulation of hormone action and cellular signaling. The journal welcomes submissions from a variety of disciplines that utilize state-of-the-art technology in systems ranging from cellular to organismal. Of particular interest to the journal are studies providing novel mechanistic insights regarding cellular and physiological processes of relevance to endocrinology that are influenced by hormones, growth factors (endocrine, paracrine and autocrine), oncogenes and their products, lymphokines, adipokines, ions, small molecule metabolic regulators, etc.
Authors should submit their full manuscript directly through the Rapid Review system, at which time it will undergo an initial prescreening. Every effort will be made to provide prompt review and rapid return of manuscripts to authors.
The following three types of articles will be considered for
publication:
(1) The bulk of the journal will be comprised of regular research papers
based on new data, previously unpublished in reviewed journals or unreviewed
publications. These papers may be of any length; however, brevity is no
contraindication for submission.
(2) Second, minireviews and overviews may be published from time
to time. If an author wishes to suggest a topic for a minireview, he or she
first should contact the editorial office of Molecular Endocrinology to
ascertain its appropriateness. Authors should include a brief section describing the search strategies used to obtain information for the review.
(3) Third, research resource articles are meant to present the most
current and important work done with microarrays, proteomics, genomics,
metabolomics, structural biology, computational biology, and computer programs,
as well as other relevant research data sets. These manuscripts are subject to
the same stringent peer review as our original research articles and
minireviews. In structure, they will differ from original research articles in
that they: 1) will not be required to contain the same mechanistic focus, and
2) generally will not exceed a total of four pages in length. Acceptance of
manuscripts will be contingent on scientific content, broad appeal, and
usefulness to studies in the area of molecular endocrinology. Authors are
encouraged to make use of our online Supplemental Data feature to present
further work that supports the content of the Research Resource submissions.
All manuscripts are treated as confidential material during the review process.
Please submit your manuscript to Molecular Endocrinology
through the Rapid Review system at the following site: http://mend.endojournals.org/.
Note that your author account will be the same for Endocrinology, Molecular
Endocrinology, The Journal of Clinical Endocrinology & Metabolism,
and Endocrine Reviews. Authors submitting manuscripts for publication in
Molecular Endocrinology are submitting their manuscript to The Endocrine
Society Central Journals Office whose database is accessible to the
Editors-in-Chief of all Endocrine Society journals.
All submissions MUST INCLUDE:
1. Cover letter. Submitted manuscripts must be accompanied by a cover letter
that describes the study's unique contribution to the field and explains why it
is appropriate for publication in Molecular Endocrinology. Specifically,
the editors would like to know what unique mechanistic contributions and
insights are offered by the paper, as well as their physiological relevance.
Authors should also provide a list of possible reviewers, and they may request
that specific reviewers not be used. Authors must also indicate that they are
submitting supplemental data when appropriate.
2. Completed Copyright Assignment & Affirmation of Originality form, which
is available at http://mend.endojournals.org/misc/RequiredForms.pdf
3. Completed Disclosure of Potential Conflict of Interest form. IMPORTANT: The corresponding
author is expected to gather EACH AUTHOR'S completed disclosure form and
fax them, together, to the editorial office along with the Author Disclosure
Summary. Do not fax them individually. Revised manuscripts WILL NOT be
processed until all signatures and the summary are received.
The Journal requires that all manuscripts be written in idiomatic English and submitted in a single-column format that follows these guidelines:
· All text should be double-spaced with 1-inch margins on both sides using 11-point type in Times Roman font.
· All lines should be numbered throughout the entire manuscript and the entire document should be paginated.
· All tables and figures must be placed after the text and must be labeled. Submitted papers must be complete, including the title page, abstract, figures, and tables. Papers submitted without all of these components will be placed on hold until the manuscript is complete.
· Authors are encouraged to cite primary literature rather than review articles in order to give credit to those who have done the original work.
The title page must include the following:
· Full title. This should be a concise statement of the article's major contents that also highlights the broad scientific impact of the study. While there is no character limit for the title, the editors may make suggestions for title revisions to enhance the manuscript's overall visibility.
· Abbreviated title of not more than 40 characters for page headings
· Authors' names and institutions. At least one person must be listed as an author; no group authorship without a responsible party is allowed. A group can be listed in the authorship line, but only on behalf of a person or persons. All group members not listed in the authorship line must be listed in the Acknowledgments section.
· All papers produced with NIH support must include the paragraph indicated in the The Endocrine Society NIH statement.
· Corresponding author's address, telephone and fax numbers, and e-mail address
· Name and address of person to whom reprint requests should be addressed
· Key words to support indexing and information retrieval
· Any grants or fellowships supporting the writing of the paper
· Disclosure summary (see Disclosure of Potential Conflict of Interest form for instructions)
· Do not exceed 250 words
· Briefly describe in complete sentences the purpose of the investigation, the methods used, the results obtained, and the principal conclusions
· Do not refer to the text or references
· Write the abstract with a general audience in mind
The article should begin with a brief introductory statement that places the work to follow in historical perspective and explains its intent and significance.
The Results section should briefly present the experimental data in text, tables, and/or figures. For details on preparation of tables and figures, see below. The Discussion should focus on the interpretation and significance of the findings with concise objective comments that describe their relation to other work in that area. The Discussion should not reiterate the Results.
These should be described and referenced in sufficient detail for other investigators to repeat the work. The source of hormones, unusual chemicals and reagents, and special pieces of apparatus should be stated. For modified methods, only the modifications need be described.
The Acknowledgments section should include the names of those people who contributed to a study but did not meet the requirements for authorship. The corresponding author is responsible for informing each person listed in the Acknowledgments section that they have been included and providing them with a description of their contribution so they know the activity for which they are considered responsible. Each person listed in the acknowledgments must give permission – in writing, if possible – for the use of his or her name. It is the responsibility of the corresponding author to collect this information.
References to the literature
should be cited in numerical order (in parentheses) in the text and listed in
the same numerical order at the end of the manuscript on a separate sheet or
sheets. There must be only one reference to a number. The number of references
cited should be kept to a reasonable minimum; to this end, appropriate recent
reviews should be cited whenever possible.
Examples of the reference style that should be used are given below. Further
examples will be found in the articles describing the Uniform Requirements for
Manuscripts Submitted to Biomedical Journals (Ann Intern Med. 1988;
208:258-265, Br Med J. 1988; 296:401-405). The titles of journals should be
abbreviated according to the style used in the Index Medicus.
If the citation formats described here do not match the formats provided in
your reference manager program, please visit the software producer's web site
for updates.
Journal articles and abstracts: List all authors. The citation of
unpublished observations, of personal communications, and of manuscripts in
preparation or submitted for publication is not permitted in the bibliography.
Such citations should be inserted at appropriate places in the text, in
parentheses and without serial number, or be presented in the footnotes. The citation of manuscripts accepted for publication but not yet in print is permitted in the bibliography provided the DOI (Digital Object Identifier) and the name of the journal in which they appear are supplied. Listing a manuscript as "in press" without a DOI and journal title is not permitted. If references to personal communications are made, authors are
encouraged to keep written proof of the exchange. If it is necessary to cite an
abstract because it contains substantive data not published elsewhere, it must
be designated at the end of the reference [e.g., 68:313 (Abstract)]. The
author is responsible for the accuracy of references.
Books: List all authors or editors.
Sample References
For general aid in the preparation of manuscripts, authors
should consult: CBE Style Manual: A Guide for Authors, Editors and Publishers.
5th ed.
Tables must be constructed as simply as possible and be intelligible without reference to the text. Each table must have a concise heading. A description of experimental conditions may appear together with footnotes at the foot of the table. Tables must not simply duplicate the text or figures. The width of the table must be designed to occupy one or two journal columns, with no more than four table columns or 8-10 table columns, respectively.
Please review the detailed instructions for preparing
digital art at http://art.cadmus.com/da/index.jsp.
E-mail queries can be sent to digitalart{at}cadmus.com.
All figures must display the figure number.
Sizing the figure: The author is responsible for providing digital art
that has been properly sized, cropped, and has adequate space between images.
Plan the size of the figure to fill 1, 1.5, or 2 columns in the printed journal
(see chart below for dimensions). In most cases, figures should be prepared for
1-column width. Produce original art at the size it should appear in the
printed journal. (Note for PowerPoint users: The sizing instructions do not
apply if you are submitting PowerPoint files for print production in E-Review.
On the submission page, check boxes to indicate that the figures are the
correct size and resolution.)
1 column = 18 picas, 7.5 cm, 3.0 in
1.5. columns = 30 picas, 12.5 cm, 5.0 in
2 columns = 38 picas, 16.0 cm, 6.5 in
Lettering: At 100% size, no lettering should be smaller than 8 point
(0.3 cm high) or larger than 12 point (0.4 cm high). Use bold and solid
lettering. Lines should be thick, solid, and no less than 1-point rule. Avoid
the use of reverse type (white lettering on a darker background). Avoid
lettering on top of shaded or textured areas. Titles should be clear and
informative. Keep wording on figures to a minimum, and confine any explanation
of figures to their separate page legends. Label only one vertical and one
horizontal side of a figure. Freehand lettering or drawing is unacceptable.
Color Figures: Figures should now be submitted as RGB (red, green, blue) format. Saving color figures to this format will be more convenient for authors as RGB is the standard default on most programs. Color images will be preserved as RGB up until the time of printing and will be posted online in their original RGB form. Using RGB color mode for online images will be a significant improvement for figures that contain fluorescent blues, reds, and greens. Therefore the online journal will accurately reflect the true color of the images the way the author intended. For print, the images will be converted to CMYK through an automated color conversion process.
Shading: Avoid the use of shading, but if unavoidable, use a coarse
rather than a fine screen setting (80-100 line screen is preferred). Avoid
1-20% and 70-99% shading; make differing shades vary by at least 20%, i.e.,
25%, 45%, 65%. Instead of shading, denote variations in graphs or drawings by
cross-hatching; solid black; or vertical, horizontal, or diagonal striping.
Avoid the use of dots.
Grouped figures: For grouped figures, indicate the layout in a diagram. Place
grouped figures so that they can be printed in 1-column width with uniform
margins. Indicate magnification in the legends and by internal reference
markers in the photographs. Their length should represent the fraction or
multiple of a micrometer, appropriate to the magnification.
Graphs: Graphs with axis measures containing very large or small numbers
should convert to easily readable notations. Example: For an ordinate range of
"counts per minute" values from 1,000 to 20,000, the true value may
be multiplied by 10-3 (scale would read from 1 to 20) and the
ordinate axis display "cpm (x10-3)." Similarly, for a
Scatchard plot with values ranging from 0.1 to 2 femtomolar (10-15
m), the scale may run from 0.1 to 2 with the abscissa labeled "m (x10-15)."
Three-dimensional bar graphs will not be published if the information they
refer to is only two-dimensional.
Supplemental Data allows authors to enhance papers in Molecular
Endocrinology by making additional substantive material available to
readers. Supplemental Data may take the form of figures, tables, datasets,
derivations, or videos, and is published only in Molecular Endocrinology
online; it does not appear in the printed version of the journal. Authors who
wish to include Supplemental Data should state so in the cover letter when the
manuscript is submitted.
Supplemental Data files should be submitted through Rapid Review at the time of
manuscript submission and will be reviewed along with the manuscript. The files
should be uploaded in the field marked "Upload Supplemental Data
Files", and should NOT be attached with the manuscript and figure files.
Authors should refer to the Supplemental Data in the manuscript at an
appropriate point in the text or figure/table legend.
The file formats listed below may be used for Supplemental Data. Provide a
brief description of each item in a separate HTML or Word file (i.e.,
figure or table legends, captions for movie or sound clips, etc.). Do not save
figure numbers, legends, or author names as part of an image. File sizes should
not exceed 5 MB. Images should not exceed 500 pixels in width or height. Do not
use tabs or spaces for Word or WordPefect tables; please use the table
functions available within these word processing programs to prepare tables.
For web pages, provide a complete list of files and instructions for creating
directories.
.htm, HTML*
.jpg, JPEG image*
.gif, Graphical image
.pdf, Adobe Portable Document Format
.xls, MS Excel Spreadsheet
.mov, Quick Time
.wav, Sound
.doc, MS Word 6 documents**
.txt, Plain ASCII*
*These files can be viewed directly on standard web browsers.
**MS Word may be used for text only.
Results should be expressed in metric units. Système Internationale (SI units) must be added in parentheses. Temperature should be expressed in degrees Celsius (e.g., 28 C) and time of day using the 24-hour clock (e.g., 0800 h, 1500 h). Do not express molecular weight in daltons. Molecular weight is considered to be the relative molecular mass of a substance, i.e., the ratio of the mass of one molecule of the substance to 1/12 of the mass of one atom of carbon 12. Therefore, molecular weight is dimensionless. The dalton is a unit of mass equivalent to 1/12 of the mass of one atom of p1 carbon 12.
All nonstandard abbreviations in the text must be defined immediately after the first use of the abbreviation. The list of Standard Abbreviations is given in the link.
Failure to notify the editor that some results in the manuscript are being or have been previously published will result in placement of a notice in the journal that the authors have violated the Ethical Guidelines for Publication of Research in The Endocrine Society Journals. The journal publishes original research and review material. Material previously published in whole or in part shall not be considered for publication. This includes materials published in any form of mass communication. At the time of submission, authors must divulge in their cover letter all prior publications or postings of the material in any form of media. Abstracts or posters displayed for colleagues at scientific meetings need not be reported. Other postings of any part of the submitted material on web pages, as well as those essential for participation in required registries will be evaluated by the Editor-In-Chief, who shall determine if those postings are material enough to constitute prior publication.
An author should have participated in either the conception or planning of the work, the interpretation of the results and the writing of the paper. An acknowledgment accompanying the paper is appropriate recognition for others who have contributed to a lesser extent, e.g., provision of clones, antisera or cell lines, or reading and reviewing manuscripts in draft. The signature of each author on the Affirmation of Originality and Copyright Release form that must be submitted with the manuscript indicates that all authors have had a part in the writing and final editing of the report, all have been given a copy of the manuscript, all have approved the final version of the manuscript, and all are prepared to take public responsibility for the work, sharing responsibility and accountability for the results.
The editors of The Endocrine Society's journals appreciate the importance of assuring unbiased authorship of editorials, reviews, and other non-research features involving selection of evidence to be discussed and perspectives to be presented. Consequently, special care is taken in choosing authors for such articles to assure their views are balanced and unencumbered, and that the Society's policies on disclosure of conflicts of interest are implemented.
The critical and confidential review of manuscripts is an
essential element of research publications. Every scientist has an obligation
to contribute to the peer review process by serving as a reviewer. Among the
obligations of reviewers is the commitment to providing an expert, critical,
and constructive scientific and literary appraisal of research reports in their
fields of knowledge, skills, and experience in a fair and unbiased manner. In
order to facilitate the prompt sharing of scientific results, it is also the
obligation of each reviewer to complete their assignments promptly, within the
editor's deadline. Should a delay in their review occur, the reviewer has the
obligation to notify the editor at once.
Reviewers should not review a manuscript if: 1) they do not think that they are
competent to assess the research described, 2) they believe there is a conflict
of interest or personal or professional relationship with the author(s) that
might bias their assessment of the manuscript, or (3) there is any other
situation that could bias their review. Employment at the same institution as
one of the authors does not automatically represent a conflict. Having
previously reviewed the article for another journal does not disqualify a
reviewer, although the editor should be informed so the reviewer's perspective
can be considered. In circumstances when reviewers need to recuse themselves,
they should notify the editor promptly, preferably with an explanation. If
reviewers are uncertain whether they should recuse themselves, they should
consult with the editor.
The reviewer should strive to provide accurate, detailed, and constructive
criticisms, and the review should be supported by appropriate references,
especially if unfavorable. The reviewer should also note whether the work of
others is properly cited. If the reviewer notes any substantial resemblance of
the manuscript being reviewed to a published paper or to a manuscript submitted
at the same time to another journal, they should promptly report this to the
editor.
No part of the manuscript under review should ordinarily be revealed to another
individual without the permission of the editor. If a reviewer consults a
colleague on a particular point, this fact, and the name of the collaborator or
consultant, should be reported to the editor, preferably in advance. With these
exceptions, a reviewer must obtain through the editor written permission from
the authors to use or disclose any of the unpublished content of a manuscript
under review.
To be considered, all clinical investigations described in submitted manuscripts must have been conducted in accordance with the guidelines in The Declaration of Helsinki and must have been formally approved by the appropriate institutional review committees or its equivalent. All manuscripts must indicate that such approval was obtained and that informed consent was obtained from subjects in all experiments involving humans. The study populations should be described in detail. In many studies details of age, race, and sex are important. However, subjects must be identified only by number or letter, not by initials or names. Photographs of patients' faces should be included only if scientifically relevant. Authors must obtain written consent from the patient for use of such photographs. For further details, see the Ethical Guidelines.
A statement confirming that all animal experimentation described in the submitted manuscript was conducted in accord with accepted standards of humane animal care, as outlined in the Ethical Guidelines, should be included in the manuscript.
Manuscripts reporting amino acid or nucleotide sequences of proteins with sequences already known from other tissues or species will be considered only if they provide new biological insight. Manuscripts dealing with partial sequence data are not likely to be considered. The Endocrine Society has established policy that deals with submission of new protein or nucleic acid sequences. When a manuscript is accepted that contains novel sequences, such sequences must be deposited in the appropriate database (such as GenBank) and an accession number obtained before the manuscript is sent to the printer. It is recommended that the following statement containing the assigned accession number be inserted as a footnote: "These sequence data have been submitted to the DDBJ/EMBL/GenBank databases under accession number Ul2345."
Manuscripts describing experiments with new compounds must provide their chemical structures. For known compounds, the source and/or literature reference to the chemical structure and characterization must be provided.
We consider papers that use genomic or proteomic approaches to study problems relevant to molecular endocrinology. We recognize that many of these will not be hypothesis driven. Nevertheless, manuscripts that utilize these approaches should go beyond cataloging and provide unique insights into regulatory networks, mechanisms, or demonstrations of biological function.
Authors submitting expression or tiling microarray datasets must clearly identify in the Materials and Methods section the platform (e.g. Affymetrix Murine Genome U74v2 Set), thoroughly describe the filtering criteria used to evaluate the raw data, and provide complete references for the statistical methods used to analyze the data. Filtered gene lists provided as supplemental data must be provided as Excel spreadsheets and not PDFs. Specific examples of supplemental data accompanying gene expression profiling manuscripts can be found in an article published in the February 2009 issue of Molecular Endocrinology (http://mend.endojournals.org/cgi/content/full/me.2008-0387/DC1).
Upon acceptance of their paper authors of microarray datasets are now required to submit the complete dataset to the Gene Expression Omnibus (GEO), the public gene expression archive of National Institute of Biotechnology Information (NCBI); OR to ArrayExpress, the corresponding database of the European Bioinformatics Institute (EBI). Submission requirements can be found at either website. Molecular Endocrinology now offers a GEO deposition service, provided at no charge by curators at our partner web resource, the Nuclear Receptor Signaling Atlas (NURSA). Please contact the editorial office for more information regarding this service.
Proteomic papers that report molecular structures, whether based on x-ray
crystallography, NMR, or computational modeling, can be accepted only after the
structural coordinates have been deposited in the Protein Data Bank: http://rcsb-deposit.rutgers.edu/
and http://pdbdep.protein.osaka-u.ac.jp/.
Assay validation: Bioassay and radioimmunoassay
potency estimates should be accompanied by an appropriate measure of the
precision of these estimates. For bioassays, these usually will be the standard
deviation, standard error of the mean, coefficient of variation, or 95%
confidence limits. For both bioassays and radioimmunoassays, it is necessary to
include data relating to within-assay and between-assay variability. If all
relevant comparisons are made within the same assay, the latter may be omitted.
Authors should be aware that the precision of a measurement depends upon its
position on the dose-response curve.
In presenting results for new assays, it is necessary to include data on the
following: 1) within-assay variability; 2) between-assay variability; 3) slope of
the dose-response curve; 4) mid-range of the assay; 5) least-detectable
concentration (concentration resulting in a response two standard deviations
away from the zero dose response); 6) data on specificity; 7) data on
parallelism of standard and unknown and on recovery; and 8) comparison with an
independent method for assay of the compound. When radioimmunoassay kits are
utilized or hormone measurements are conducted in other than the authors'
laboratories and the assay is central to the study, data regarding performance
characteristics should be included.
Pulse analysis: Data from studies of pulsatile hormone secretion should
be analyzed using a validated, objective pulse detection algorithm. The
algorithm used should require that false-positive rates of pulse detection be
defined in relation to the measurement error of the data set being analyzed,
and the methods used to determine the measurement error should be described.
The author(s) also should describe the methods used: 1) to deal with missing or
undetectable values; 2) to determine peak frequency, interpeak interval, and
pulse amplitude; and 3) For statistical comparisons of peak parameters.
Data analysis: It is the author's responsibility to document that the
results are reproducible and that the differences found are not due to random
variation. No absolute rules can be applied, but in general quantitative data
should be from no fewer than three replicate experiments. Appropriate
statistical methods should be used to test the significance of differences in
results. The term "significant" should not be used unless statistical
analysis was performed, and the probability value used to identify significance
(e.g., P > 0.05) should be specified.
When several t tests are employed, authors should be aware that nominal
probability levels no longer apply. Accordingly, the multiple t test, multiple
range test, or similar techniques to permit simultaneous comparisons should be
employed. Also, in lieu of using several t tests, it is often more appropriate
to utilize an analysis of variance (ANOVA) to permit pooling of data, increase
the number of degrees of freedom, and improve reliability of results. Authors
should use appropriate nonparametric tests when the data depart substantially
from a normal distribution.
Analysis of variance tables should not be inserted in manuscripts. F values
with the degrees of freedom as subscripts together with the P values are
sufficient.
In presenting results of linear regression analyses, it is desirable to show
95% confidence limits.
When data points are fitted with lines (as in Scatchard or Lineweaver-Burk
plots), the method used for fitting (graphical, least squares, computer
program) should be specified. If differences in slopes and/or axis intercepts
are claimed for plotted lines, these should be supported by statistical
analysis.
Useful references for statistical methods are McArthur, J. W., and T. Colten
(eds.), Statistics in Endocrinology, MIT Press,
Authors should include in the manuscript a list of the software used for statistical analyses.
When preparing digital images, authors must adhere to the following guidelines as stated in the CSE's White Paper on Promoting Integrity in Scientific Journal Publications:
· No specific feature within an image may be enhanced, obscured, moved, removed, or introduced.
· Adjustments of brightness, contrast, or color balance are acceptable if they are applied to the entire image and as long as they do not obscure, eliminate, or misrepresent any information present in the original.
· The grouping of images from different parts
of the same gel, or from different gels, fields, or exposures must be made
explicit by the arrangement of the figure (e.g., dividing lines) and in the
figure legend.
Deviations from these guidelines will be considered as potential ethical
violations.
Note that this is an evolving issue, but these basic principles apply
regardless of changes in the technical environment. Authors should be aware
that they must provide original images when requested to do so by the
Editor-in-Chief who may wish to clarify an uncertainty or concern.
[Please see paper of Rossner and Yamada (Journal of Cell Biology, 2004,
166:11-15), which was consulted in developing these policy issues, for
additional discussion, and the CSE's White Paper on Promoting Integrity in
Scientific Journal Publications, published by the Council of Science Editors,
2006.]
Proofs and a reprint order form are sent to the corresponding author unless the Editorial Office is advised otherwise. The author should designate by footnote on the title page of the manuscript the name and address of the person to whom reprint requests should be directed. Questions about reprints should be referred to Cadmus Professional Communications at 410-819-3912 (direct) or 800-407-9190 (toll-free).
There is no submission fee for The Endocrine Society
journals.
There will be a charge of $90 per printed page for members of The Endocrine
Society and $110 per printed page for non-members. There will be a charge of
$235 per color figure for members of The Endocrine Society and $735 per color
figure for non-members. Authors must submit usable digital art that passes
Cadmus's Rapid Inspector. Queries on page charges may be directed to Joy Carter
at Cadmus Professional Communications (410-691-6439; fax 410-684-2792).
For articles that were funded by NIH, accepted manuscripts will be submitted to PubMed Central. These manuscripts will be made freely available online twelve months after print publication. NIH will contact the author to confirm submission.
The Wellcome Trust requires electronic copies of any research papers that are accepted for publication in a peer-reviewed journal, and are supported in whole or in part by Wellcome Trust funding, be made available through PMC as soon as possible and in any event within 6 months of the journal publisher's official date of final publication. The Endocrine Society will offer authors supported by the Wellcome Trust the option of meeting the publication requirements of the Trust by paying for an open access option. The cost to authors would be $3,000 and would presumably be paid by the Wellcome Trust. Authors who wish to have their papers published with immediate access should contact the appropriate Journal office upon acceptance of their paper. Upon receipt of payment, the final print version will be deposited in PMC for immediate open access. These articles will be licensed using the Creative Commons, Attribution, Non-commercial license 2.0.
Authors may deposit the final PDF version of their manuscript in their institutional repository or other archive 1 year following the date of print publication. Any deposits to be made prior to 1 year following the date of print publication must be approved by the Publications Department of The Endocrine Society.
Publisher: The
Endocrine Society
Editor-in-Chief: Donald B. DeFranco, Ph.D.
Editorial Board: Molecular Endocrinology Editorial Board
Impact Factor 2008: 5.389
5-Year Impact Factor 2008: 5.432
Frequency of Publication: Monthly
Print Journal Circulation: 2,001
ISSN (print journal): 0888-8809
ISSN (online): 1944-9917
Indexing: EMBASE / Excerpta Medica, National Biological Service, Current
Contents, BIOSIS, Index Medicus, Elsevier BIOBASE / Current Awareness in
Biological Sciences, and Sociedad Iberoamericana de Información Cientifica
(SIIC)
Supplements: Contact Editorial Office for more information
Contact:
Editorial Office: The Endocrine Society
Molecular Endocrinology
8401 Connecticut Avenue, Suite 900
Chevy Chase, MD 20815-5817 USA
Phone: 301-951-2603
Fax: 301-951-2617
Email: molendo{at}endo-society.org
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |